Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2005 1
2006 1
2007 5
2008 2
2009 3
2010 2
2011 1
2012 1
2013 3
2014 3
2015 2
2016 2
2018 3
2019 3
2020 1
2021 1
2022 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

33 results

Results by year

Filters applied: . Clear all
Page 1
Optimizing CDK4/6 inhibitors in advanced HR+/HER2- breast cancer: A personalized approach.
Fontanella C, Giorgi CA, Russo S, Angelini S, Nicolardi L, Giarratano T, Frezzini S, Pestrin M, Palleschi D, Bolzonello S, Parolin V, Haspinger ER, De Rossi C, Greco F, Gerratana L. Fontanella C, et al. Among authors: pestrin m. Crit Rev Oncol Hematol. 2022 Dec;180:103848. doi: 10.1016/j.critrevonc.2022.103848. Epub 2022 Oct 17. Crit Rev Oncol Hematol. 2022. PMID: 36257536 Free article. Review.
Clinical outcomes after palbociclib with or without endocrine therapy in postmenopausal women with hormone receptor positive and HER2-negative metastatic breast cancer enrolled in the TREnd trial.
Rossi L, Biagioni C, McCartney A, Migliaccio I, Curigliano G, Sanna G, Moretti E, Minisini AM, Cinieri S, Tondini C, Arpino G, Bernardo A, Martignetti A, Risi E, Pestrin M, Boni L, Benelli M, Biganzoli L, Di Leo A, Malorni L. Rossi L, et al. Among authors: pestrin m. Breast Cancer Res. 2019 May 29;21(1):71. doi: 10.1186/s13058-019-1149-5. Breast Cancer Res. 2019. PMID: 31142370 Free PMC article.
Prognostic role of serum thymidine kinase 1 activity in patients with hormone receptor-positive metastatic breast cancer: Analysis of the randomised phase III Evaluation of Faslodex versus Exemestane Clinical Trial (EFECT).
McCartney A, Biagioni C, Schiavon G, Bergqvist M, Mattsson K, Migliaccio I, Benelli M, Romagnoli D, Bonechi M, Boccalini G, Pestrin M, Galardi F, De Luca F, Biganzoli L, Piccart M, Gradishar WJ, Chia S, Di Leo A, Malorni L. McCartney A, et al. Among authors: pestrin m. Eur J Cancer. 2019 Jun;114:55-66. doi: 10.1016/j.ejca.2019.04.002. Epub 2019 May 3. Eur J Cancer. 2019. PMID: 31059974 Clinical Trial.
The role of abemaciclib in treatment of advanced breast cancer.
McCartney A, Moretti E, Sanna G, Pestrin M, Risi E, Malorni L, Biganzoli L, Di Leo A. McCartney A, et al. Among authors: pestrin m. Ther Adv Med Oncol. 2018 May 31;10:1758835918776925. doi: 10.1177/1758835918776925. eCollection 2018. Ther Adv Med Oncol. 2018. PMID: 29899762 Free PMC article. Review.
Plasma thymidine kinase-1 activity predicts outcome in patients with hormone receptor positive and HER2 negative metastatic breast cancer treated with endocrine therapy.
Bonechi M, Galardi F, Biagioni C, De Luca F, Bergqvist M, Neumüller M, Guarducci C, Boccalini G, Gabellini S, Migliaccio I, Di Leo A, Pestrin M, Malorni L. Bonechi M, et al. Among authors: pestrin m. Oncotarget. 2018 Mar 27;9(23):16389-16399. doi: 10.18632/oncotarget.24700. eCollection 2018 Mar 27. Oncotarget. 2018. PMID: 29662653 Free PMC article.
33 results